Literature DB >> 23700333

Increased prevalence of sleep-disordered breathing in Friedreich ataxia.

Louise A Corben1, Michael Ho, Janet Copland, Geneieve Tai, Martin B Delatycki.   

Abstract

OBJECTIVES: We sought to document the prevalence and nature of sleep-disordered breathing (SDB) in individuals with Friedreich ataxia (FRDA) as well as establish the relationship, if any, between SDB and clinical parameters of FRDA.
METHODS: Eighty-two individuals with FRDA were administered the Epworth Sleepiness Scale on an annual basis for up to 3 years. Individuals were referred for a sleep study if they had an Epworth Sleepiness Scale score >8 or had clinical symptoms suggestive of SDB.
RESULTS: From this cohort, 21 individuals underwent a sleep study and 17 were diagnosed with obstructive sleep apnea syndrome, giving a minimum prevalence of 21%, which is greater than that found in the general population (3%-7%). Moreover, the presence of obstructive sleep apnea was significantly correlated with the duration of disease and clinical severity of FRDA.
CONCLUSION: It is recommended that individuals with FRDA undergo regular screening for obstructive sleep apnea to identify the need for a sleep study and subsequent treatment if SDB is diagnosed.

Entities:  

Mesh:

Year:  2013        PMID: 23700333     DOI: 10.1212/WNL.0b013e318297ef18

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Sleep in Huntington's disease: a systematic review and meta-analysis of polysomongraphic findings.

Authors:  Ye Zhang; Rong Ren; Linghui Yang; Junying Zhou; Yun Li; Jie Shi; Lin Lu; Larry D Sanford; Xiangdong Tang
Journal:  Sleep       Date:  2019-10-09       Impact factor: 5.849

Review 2.  Sleep Disorders in Hereditary Ataxias.

Authors:  Lucio Huebra; Fernando Morgadinho Coelho; Flávio Moura Rezende Filho; Orlando G Barsottini; José Luiz Pedroso
Journal:  Curr Neurol Neurosci Rep       Date:  2019-07-25       Impact factor: 5.081

Review 3.  Friedreich ataxia: clinical features and new developments.

Authors:  Medina Keita; Kellie McIntyre; Layne N Rodden; Kim Schadt; David R Lynch
Journal:  Neurodegener Dis Manag       Date:  2022-06-29

4.  Comorbidities in Friedreich ataxia: incidence and manifestations from early to advanced disease stages.

Authors:  Mario Fichera; Anna Castaldo; Alessia Mongelli; Gloria Marchini; Cinzia Gellera; Lorenzo Nanetti; Caterina Mariotti
Journal:  Neurol Sci       Date:  2022-09-02       Impact factor: 3.830

5.  Functional connectivity of the human hypothalamus during wakefulness and nonrapid eye movement sleep.

Authors:  Jun Jiang; Guangyuan Zou; Jiayi Liu; Shuqin Zhou; Jing Xu; Hongqiang Sun; Qihong Zou; Jia-Hong Gao
Journal:  Hum Brain Mapp       Date:  2021-05-07       Impact factor: 5.038

Review 6.  Consensus clinical management guidelines for Friedreich ataxia.

Authors:  Louise A Corben; David Lynch; Massimo Pandolfo; Jörg B Schulz; Martin B Delatycki
Journal:  Orphanet J Rare Dis       Date:  2014-11-30       Impact factor: 4.123

7.  Sleep disordered breathing in children with mitochondrial disease.

Authors:  Ricardo A Mosquera; Mary Kay Koenig; Rahmat B Adejumo; Justyna Chevallier; S Shahrukh Hashmi; Sarah E Mitchell; Susan E Pacheco; Cindy Jon
Journal:  Pulm Med       Date:  2014-12-23

8.  Assessment of Sleep Spindle Density among Genetically Positive Spinocerebellar Ataxias Types 1, 2, and 3 Patients.

Authors:  Doniparthi Venkata Seshagiri; Ragasudha Botta; Arun Sasidharan; Pramod Kumar Pal; Sanjeev Jain; Ravi Yadav; Bindu M Kutty
Journal:  Ann Neurosci       Date:  2018-03-08

Review 9.  Friedreich's ataxia: clinical features, pathogenesis and management.

Authors:  A Cook; P Giunti
Journal:  Br Med Bull       Date:  2017-12-01       Impact factor: 4.291

Review 10.  Sleep and sleep disorders in rare hereditary diseases: a reminder for the pediatrician, pediatric and adult neurologist, general practitioner, and sleep specialist.

Authors:  Natan Gadoth; Arie Oksenberg
Journal:  Front Neurol       Date:  2014-07-17       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.